Depressive symptoms and intellectual functioning in anxiety patients treated with clorazepate.
The combined data from two 1970s anxiety studies that used clorazepate and placebo as controls were reanalyzed statistically with a focus on intellectual functioning and depressive symptoms. For the 176 patients given either clorazepate or placebo, significant improvement was observed on the mean scores of the intellectual item and the depressive item of the Hamilton Rating Scale for Anxiety; the clorazepate group was significantly more improved than the placebo group. Similar results were observed in patients' self-ratings. The authors conclude that clorazepate is effective in treating depressive symptoms and improving intellectual functioning in patients with generalized anxiety disorder.
D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D001288:Attention / Q000187:drug effects; D002986:Clinical Trials as Topic; D003009:Clorazepate Dipotassium / Q000009:adverse effects / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D003863:Depression / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D010555:Personality Inventory; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D013850:Thinking / Q000187:drug effects
D014151:Anti-Anxiety Agents; D010919:Placebos; D003009:Clorazepate Dipotassium